|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011. Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues. Cleveland-based Athersys, with a market value of about $200 million, demonstrated evidence in a midstage trial that its therapy may be able to expand the emergency treatment window for major strokes to up to 36 hours, compared with about four hours with current drugs, potentially allowing many more patients to avoid crippling disabilities.
US Auto Parts Network Inc (NASDAQ:PRTS), a online retail company based in United States, saw a significant share price rise of over 20% in the past couple of months onRead More...
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess CTI BioPharma Corp’s (NASDAQ:CTIC) track record on aRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to U.S. Auto Parts Network, Inc. Here are 5 ETFs with the largest exposure to PRTS-US. Comparing the performance and risk of U.S. Auto Parts Network, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Live Ventures, Inc. Here are 5 ETFs with the largest exposure to LIVE-US. Comparing the performance and risk of Live Ventures, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Pharmaceutical giant Allergan PLC (AGN) will acquire The Woodlands-based Repros Therapeutics Inc. (RPRX), a company that develops drugs to treat male and female reproductive disorders, according to a Dec. 12 press release. A subsidiary of Ireland-based Allergan will purchase all of the outstanding shares of Repros common stock through a cash tender offer for 67 cents per share. Allergan — formerly Actavis PLC — reported net revenue of $14.57 billion in 2016, according to its annual report.
Today I will take a look at First Internet Bancorp’s (NASDAQ:INBK) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...
Today, I will be analyzing Repros Therapeutics Inc’s (NASDAQ:RPRX) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
When Globus Maritime Limited’s (NASDAQ:GLBS) announced its latest earnings (30 June 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Himax Technologies Inc (NASDAQ:HIMX) with a market capitalization of $2.29B, rarely draw their attention from analysts andRead More...
Himax Technologies (NASDAQ:HIMX) is a semiconductor company that may have met its match: lackluster 3D sensing revenue just around the corner. Rosenblatt analyst Jun Zhang is a bear anticipating roughly 54% downside potential for the Taiwanese fabless semiconductor firm that he believes simply cannot live up to its own 3D sensing revenue expectations in 2018.
Roth Capital analyst Suji Desilva is bumping up the assurance factor when it comes to Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) and its opportunity as a "differentiated investment." The Taiwanese fabless semiconductor firm is already tracking past the analyst's prior estimate for the fourth quarter, leading Desilva to rev up his price target and look forward with confidence to a 3D sensing-centered 2018 primed for growth.
With supply issues addressed and an industry-leading technology ready for customers, the display driver upstart is poised to grow.
For Repros Therapeutics Inc’s (NASDAQ:RPRX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. RPRX is exposedRead More...
The Vetr crowd on Tuesday upgraded its rating on Himax Technologies, Inc. (NASDAQ: HIMX ) from 1.5 stars (Strong Sell), issued four days ago, to 4.5 stars (Strong Buy). Crowd sentiment at the time of the ...
Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Himax Technologies and Eco-Stim Energy Solutions are examples of many potential outperformers thatRead More...